Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
6 hours ago
- #Thyroid Cancer Risk
- #Meta-Analysis
- #Incretin-Based Therapy
- No statistically significant association found between incretin-based therapies and thyroid cancer risk in RCTs.
- Meta-analysis included 15 RCTs with 84,237 participants, reporting 28 thyroid cancer events in treatment groups vs. 15 in control groups.
- Pooled odds ratio was 1.52 (95% CI 0.86-2.68) with no significant heterogeneity (I² = 0.0%).
- Evidence rated as very low certainty due to imprecision from rare events, limiting conclusive findings.
- Long-term surveillance is recommended to rule out a clinically relevant increase in risk.